Welfare to Web to Work: Internet Job Searching Among Former Welfare Clients in Florida

This study provides the first empirical test of whether searching for jobs on the Internet can help people gain access to high quality jobs. Using new data from former welfare clients in Florida, we present results from a multivariate regression analysis of Internet job searching on wages and on a number of job benefits. On average, Internet job searchers receive better jobs than people who conducted more traditional job searches, net of numerous control variables. These findings suggest that welfare recipients have a great deal to gain from searching for their jobs on the Internet

Why the extensive use of executive orders by state governors may not be a threat to democracy

Like the president, state Governors frequently make use of executive orders in order to pursue their agendas. But do these unilateral actions undermine democracy? No, argue Alexandra G. Cockerham and Robert E. Crew, Jr, who find that legislatures can be willing to delegate policy-making authority to governors if they are of the same party or if the legislature is fragmented

The Covid-19 pandemic shows the power and limits of American federalism

While there has been a great deal of attention paid to how President Trump has responded to the Covid-19 pandemic, Alexandra Cockerham and Robert E. Crew Jr. argue that, to get a true sense of the country’s response, we should look at the actions of state governors and mayors within states. While the federal government has tried to coordinate some efforts, federalism has meant that governors and local administrators have been able to adapt their responses, with the hardest hit states like New York setting a precedent for others

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidence of a pharmacodynamic effect, to recommend a dose level for phase II trials. This was an open-labelled, nonrandomised dose-escalation phase I study. In all, 12 patients with a history of recurrent superficial bladder cancer were grouped into four dose levels (10–150 mg ml−1 in 60 ml saline). Six catheter instillations at weekly intervals were used. Cystoscopy and biopsy were performed before and 3 months after the start of treatment. Suramin was assayed using high-performance liquid chromatography, vascular endothelial growth factor (VEGF) using ELISA (enzyme-linked immunosorbent assay), and urinary protein profile using surface-enhanced laser desorption ionisation mass spectroscopy (SELDI). Minimal systemic absorption of Suramin was found at the highest dose of 150 mg ml−1. Urinary VEGF was affected by Suramin at doses above 50 mg ml−1, corresponding to the estimated threshold of saturation of Suramin binding to urine albumin. SELDI showed a specific disappearance of urinary protein peaks during treatment. Intravesical Suramin shows lack of toxicity and low systemic absorption. The results of this phase I trial support expanded clinical trials of efficacy at a dose of 100 mg ml−1 intravesically

Small, Low-energy, Dispersive Solar Energetic Particle Events Observed by Parker Solar Probe

The Energetic Particle Instrument–Low Energy (EPI-Lo) experiment has detected several weak, low-energy (~30–300 keV nucleon⁻¹) solar energetic particle (SEP) events during its first two closest approaches to the Sun, providing a unique opportunity to explore the sources of low-energy particle acceleration. As part of the Parker Solar Probe (PSP) Integrated Science Investigation of the Sun (IS⊙IS) suite, EPI-Lo was designed to investigate the physics of energetic particles; however, in the special lowest-energy "time-of-flight only" product used in this study, it also responds to solar photons in a subset of approximately sunward-looking apertures lacking special light-attenuating foils. During the first three perihelia, in a frame rotating with the Sun, PSP undergoes retrograde motion, covering a 17° heliographic longitudinal range three times during the course of the ~11-day perihelion passes, permitting a unique spatial and temporal study into the location, correlation, and persistence of previously unmeasurable SEPs. We examine the signatures of these SEPs (during the first PSP perihelion pass only) and the connection to possible solar sources using remote observations from the Solar Dynamics Observatory (SDO), the Solar TErrestrial RElations Observatory (STEREO), and the ground-based Global Oscillation Network Group (GONG). The orientation of the Sun relative to STEREO, SDO, and GONG makes such identifications challenging, but we do have several candidates, including an equatorial coronal hole at a Carrington longitude of ~335°. To analyze observations from EPI-Lo, which is a new type of particle instrument, we examine instrumental effects and provide a preliminary separation of the ion signal from the photon background

Persistent Tn polyagglutination syndrome during febrile neutropenia: a case report and review of the literature

<p>Abstract</p> <p>Introduction</p> <p>Tn polyagglutination syndrome is a rare disorder that has been reported on only a few occasions in the literature, and, to the best of our knowledge, never before in the context of febrile neutropenia.</p> <p>Case presentation</p> <p>We report the case of a 26-year-old Caucasian woman who presented to our emergency department complaining of a persistent fever over the previous three days. She had a history of long-standing refractory pancytopenia with multi-lineage dysplasia and severe neutropenia, but she had rarely experienced infection. The results of a physical examination and multiple laboratory tests were unremarkable. While investigating the possible causes of the refractory, long-standing pancytopenia, the possibility of a polyagglutinable state was suggested. Blood samples were sent to the laboratory for an analysis of mixed-field seed lectin agglutination assay. A serum lectin panel confirmed the final diagnosis of Tn-activation.</p> <p>Conclusions</p> <p>We should include Tn-activation in our differential whenever we encounter cases of refractory long-standing idiopathic cytopenias and inconclusive bone marrow results displaying multi-lineage dysplasia. Novel genetic techniques have recently revealed the interesting pathophysiology of this phenomenon. The recognition and inclusion of Tn polyagglutination syndrome in our differential diagnoses has important clinical implications, given its main associated features, such as severe thrombocytopenia and neutropenia, which are usually linked to a benign clinical course and prognosis. Increased awareness of the polyagglutinable disorders will potentially decrease the need for invasive and costly medical interventions and also raises the need for monitoring of this specific sub-set of patients. In addition, the study of the expression and implications of Tn, and other similar antigens, offers a fascinating perspective for the study of its role in the diagnosis, prognosis and immunotherapy of solid tumors and hematological malignancies. The infrequency with which Tn polyagglutination syndrome is encountered, its clinical features and its pathophysiology make it a formidable diagnostic challenge.</p

The decline in stomach cancer mortality: exploration of future trends in seven European countries

Mortality from stomach cancer has fallen steadily during the past decades. The aim of this paper is to assess the implication of a possible continuation of the decline in stomach cancer mortality until the year 2030. Annual rates of decline in stomach cancer mortality from 1980 to 2005 were determined for the Netherlands, United Kingdom, France, and four Nordic countries on the basis of regression analysis. Mortality rates were extrapolated until 2030, assuming the same rate of decline as in the past, using three possible scenarios. The absolute numbers of deaths were projected taking into account data on the ageing of national populations. Stomach cancer mortality rates declined between 1980 and 2005 at about the same rate (3.6–4.9% per year) for both men and women in all countries. The rate of decline did not level off in recent years, and it was not smaller in countries with lower overall mortality rates in 1980. If this decline were to continue into the future, stomach cancer mortality rates would decline with about 66% between 2005 and 2030 in most populations, while the absolute number of stomach cancer deaths would diminish by about 50%. Thus, in view of the strong, stable and consistent mortality declines in recent decades, and despite population ageing, stomach cancer is likely to become far less important as a cause of death in Europe in the future

Male breast cancer

Male breast cancer (MBC) is a rare disease representing less than 1% of all breast cancers (BC) and less than 1% of cancers in men. Age at presentation is mostly in the late 60s. MBC is recognized as an estrogen-driven disease, specifically related to hyperestrogenism. About 20% of MBC patients have family history for BC. Mutations in BRCA1 and, predominantly, BRCA2, account for approximately 10% of MBC cases. Because of its rarity, MBC is often compared with female BC (FBC). Based on age-frequency distribution, age-specific incidence rate patterns and prognostic factors profiles, MBC is considered similar to late-onset, postmenopausal estrogen/progesterone receptor positive (ER+/PR+) FBC. However, clinical and pathological characteristics of MBC do not exactly overlap FBC. Compared with FBC, MBC has been reported to occur later in life, present at a higher stage, and display lower histologic grade, with a higher proportion of ER+ and PR+ tumors. Although rare, MBC remains a substantial cause for morbidity and mortality in men, probably because of its occurrence in advanced age and delayed diagnosis. Diagnosis and treatment of MBC generally is similar to that of FBC. Men tend to be treated with mastectomy rather than breast-conserving surgery. The backbone of adjuvant therapy or palliative treatment for advanced disease is endocrine, mostly tamoxifen. Use of FBC-based therapy led to the observation that treatment outcomes for MBC are worse and that survival rates for MBC do not improve like FBC. These different outcomes may suggest a non-appropriate utilization of treatments and that different underlying pathogenetic mechanisms may exist between male and female BC

The Victorian Newsletter (Fall 1978)

The Victorian Newsletter is sponsored for the Victorian Group of the Modern Language Association by the University of Florida and is published twice annually.Ironic Translation in Fifine at the Fair / Dorothy Mermin -- The Heroine of Middlemarch / Gordon S. Haight -- How Many Children had Barry Lyndon? / Winslow Rogers -- Martin Chuzzlewit: The Art of the Critical Imagination / David D. Marcus -- A New Carlyle Manuscript / Roger L. Tarr -- Disraeli's Sybil and Hollinshed's Chronicles / Lois E. Bueler -- Thackeray in Elizabeth Gaskell's The Life of Charlotte Brontë: Some Manuscript & Evidence / Angus Easson -- Dickens with a Voice like Burke's / Louie Crew -- In Defense of Margaret: Another Look at Arnold's "The Forsaken Merman" / Frank R. Giordano, Jr. -- Yeats, Tennyson, and "Innisfree" / Gary Sloan -- Victorian Group New

Blood group terminology 2004: from the International Society of Blood Transfusion committee on terminology for red cell surface antigens

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/73460/1/j.1423-0410.2004.00564.x.pd